Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunothera ...
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual MeetingPre-clinical data on Medicenna’s first-in-class Masked and ...
The essential roles of common gamma cytokines such as interleukin (IL)-2, IL-7, and IL-15 in the commitment ... NK cells utilize unique signaling pathways that offer exclusive ways to genetically ...
The ability to distinguish self from altered-self or missing-self, paired with potent and diverse effector ... effect on NK cell survival, proliferation and cytotoxicity are additionally dependent on ...
For instance, recent study demonstrated that IL-15-engineered γδT cells exhibited self-sustained ... some tumor-reactive γδT cells retain effector function despite expressing PD-1. Checkpoint blockade ...
CD8 T cells lacking Tet1/3 preferentially differentiate into short-lived effector and effector memory cells following acute ...
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback